Cytosorbents Corporation CTSO
$5.75
$0.020.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -326.80% | -246.79% | 27.36% | -14.52% | 145.35% |
| Total Depreciation and Amortization | -14.55% | -7.16% | -9.41% | -6.53% | -1.52% |
| Total Amortization of Deferred Charges | 47.64% | 53.16% | 30.37% | 0.00% | 1,885.05% |
| Total Other Non-Cash Items | 129.59% | 193.55% | -79.45% | 145.49% | -392.47% |
| Change in Net Operating Assets | 25.93% | 416.92% | 6.35% | -156.29% | 145.75% |
| Cash from Operations | 61.37% | 66.47% | -106.11% | -4.63% | 68.52% |
| Capital Expenditure | 62.16% | -450.00% | -56.52% | 88.82% | -107.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 60.00% | -35.56% | -370.91% | 148.98% | 6.13% |
| Cash from Investing | 105.30% | 2.13% | -134.68% | 118.39% | -10.92% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | 1,383.83% | 100.00% | -100.00% |
| Foreign Exchange rate Adjustments | -31.52% | -914.29% | 1,374.53% | -271.76% | 468.19% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 71.10% | -142.92% | 46.46% | 3.89% | -128.53% |